AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06059495
Drug: Dostarlimab
RxNorm normalized name: Dostarlimab
DrugBank: Dostarlimab (DB15627)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: After inclusion: dostarlimab 500mg IV 30min q3w (± 2-3 days) for 4 cycles (C1-C4)~Then:~At wk12 • If cCR: dostarlimab 1000mg q6w for 2 cycles (C5-C6)~• If downstaging at UGI endoscopy, and no disease progression (PD)/or mets on TAP-CT, \<3 biopsies with tumor cells: dostarlimab 500mg q3w for 4 cycles (C5-C8)~• If loco/loco-regional PD on TAP-CT, macroscopic tumor on UGI endoscopy, no distant mets, and \>2 positive biopsies at wk12 followed by surgery and if Becker-TRG 1a, 1b, or 2 after surgery: dostarlimab 1000mg q6w for 6 cycles (C5-C10)~At 24wk~• If cCR at 12 and 24 wks: dostarlimab 1000mg q6w for 4 cycles (C7-C10)~• If downstaging at UGI endoscopy without PD on CT at wk 12 with \<3 biopsies with tumor cells at wk12 and cCR: dostarlimab 1000mg q6w for 4 cycles (C9-C12)~• If downstaging at UGI endoscopy without PD on CT at wk 12 with and no cCR, surgery will be proposed and if Becker-TRG 1a, 1b, or 2 after surgery: dostarlimab 1000mg q6w for 4 cycles (C9-C12)
Trial: NCT06303739
Drug: psilocybin
RxNorm normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25mg of psilocybin administered during treatment session, accompanied by preparation before, integration after, and assistive therapy during the session.
Trial: NCT05566223
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day -7 to Day -3 : Fludarabine 25 mg/m\^2/dose as a 1 hour intravenous infusion per institutional guidelines once a day for 5 doses beginning on Day -7. Fludarabine will be started approximately 1 to 2 hours after the cyclophosphamide on Day -6 and Day -5.
Trial: NCT05566223
Drug: Aldesleukin
RxNorm normalized name: Aldesleukin
DrugBank: Aldesleukin (DB00041)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Days 1-4 : Aldesleukin at 720,000 U/kg as an intravenous infusion, every 8 -12 hours but, no more than 24 hours apart as tolerated for up to 6 doses.
Trial: NCT05566223
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered as maintenance therapy in some patients starting at first follow-up (400 mg/dose starting Day 28 /Week 4 then every 6 weeks thereafter until disease progression, unacceptable toxicity, or up to 24 months)
Trial: NCT06217367
Drug: 50 mg Diphenhydramine
DrugBank: Diphenhydramine (DB01075)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants ingest 50mg of diphenhydramine orally \~2 hours prior to a passive heating protocol. Participants then don a water-perfusion heat suited and lay supine on assessment table while 49℃ is circulated throughout the garment. Heating persists until participants reach a 1.5℃ increase in core temperature from baseline.
Trial: NCT06217367
Drug: 10 mg Loratadine
RxNorm normalized name: loratadine 10 MG
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants ingest 10 mg of loratadine orally \~2 hours prior to a passive heating protocol. Participants then don a water-perfusion heat suited and lay supine on assessment table while 49℃ is circulated throughout the garment. Heating persists until participants reach a 1.5℃ increase in core temperature from baseline.
Trial: NCT06217367
Drug: 5 mg Desloratadine
RxNorm normalized name: desloratadine 5 MG
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants ingest 5 mg of desloratadine orally \~2 hours prior to a passive heating protocol. Participants then don a water-perfusion heat suited and lay supine on assessment table while 49℃ is circulated throughout the garment. Heating persists until participants reach a 1.5℃ increase in core temperature from baseline.
Trial: NCT06233097
Drug: Esomeprazole magnesium dihydrate-Test product
RxNorm normalized name: esomeprazole magnesium dihydrate
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Esomeprazole magnesium dihydrate 40 mg tablets Manufactured by: Cipla Limited, India
Trial: NCT06233097
Drug: Esomeprazole magnesium dihydrate-Reference product
RxNorm normalized name: esomeprazole magnesium dihydrate
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Esomeprazole magnesium dihydrate 40 mg tablets Manufactured by: AstraZeneca AB, Kingdom of Sweden
Trial: NCT05688020
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid will be injected as part of the injectate during endoscopic resection.
Trial: NCT04962425
Drug: Trastuzumab
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Trastuzumab \[Herceptin\] is a recombinant DNA-humanized monoclonal antibody that selectively targets the HER-2 receptor on the surface of tumor cells.
Trial: NCT00002292
Drug: Pentamidine isethionate
RxNorm normalized name: Pentamidine Isethionate
DrugBank: Pentamidine (DB00738)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05263921
Drug: PF-07321332/ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Single oral dose of PF-07321332/ritonavir under fasted conditions
Trial: NCT05263921
Drug: PF-07321332/ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Single oral dose of PF-07321332/ritonavir mixed with water under fasted conditions
Trial: NCT05263921
Drug: PF-07321332/ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Single oral dose of PF-07321332/ritonavir mixed with applesauce under fasted conditions
Trial: NCT05263921
Drug: PF-07321332/ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Single oral dose of PF-07321332/ritonavir mixed with vanilla pudding under fasted conditions
Trial: NCT06440915
Drug: Isavuconazole
RxNorm normalized name: Isavuconazole
DrugBank: Isavuconazole (DB11633)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isavuconazole
Trial: NCT06158698
Drug: Colchicine
RxNorm normalized name: Colchicine
DrugBank: Colchicine (DB01394)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Colchicine 1 mg daily (or 0.5 mg daily il weight \<70 kg) from randomization for 180 days (6 months)
Trial: NCT04866017
Drug: Tislelizumab
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg intravenously every three weeks
Trial: NCT04866017
Drug: Durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 10 milligrams per kilogram (mg/kg) intravenously once every 2 weeks (or 1500 mg intravenously once every 4 weeks where the dosage has been approved by a local health authority)
Trial: NCT04866017
Drug: Ociperlimab
RxNorm normalized name: Ociperlimab
DrugBank: Ociperlimab (DB18947)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 900 milligrams (mg) intravenously every three weeks
Trial: NCT05282420
Drug: Ranibizumab
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ranibizumab
Trial: NCT05282420
Drug: Aflibercept
RxNorm normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Aflipercept
Trial: NCT04711889
Drug: Ulinastatin
RxNorm normalized name: ulinastatin
DrugBank: Ulinastatin (DB12038)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ulinastatin is taken three times a day.
Trial: NCT05119894
Drug: Brexpiprazole LAI: Dose 1
DrugBank: Brexpiprazole (DB09128)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cohort 1: Single Dose Intramuscular Injection: Brexpiprazole LAI Dose 1
Trial: NCT05119894
Drug: Brexpiprazole LAI: Dose 2
DrugBank: Brexpiprazole (DB09128)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cohort 2: Single Dose Intramuscular Injection:Brexpiprazole LAI Dose 2
Trial: NCT05603468
Drug: platelet rich plasma
RxNorm normalized name: Platelet Rich Plasma
DrugBank: Platelet Rich Plasma (DB19295)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platelet rich plasma group: after the surgery of rotator arthroscopic rotator cuff repair, 3ml PRP (LongTai Biological Company) was injected into the rotator cuff tear under the rotator arthroscope for a time. PRP production process: before anesthesia, 20ml arterial blood was drawn and injected into the PRP tube. The blood was fully oscillated in the tube, and then placed in a centrifuge with 1500g for 9min to remove excess plasma and make 5ml PRP. 3ml is used for injection and 2ml is used for quality control.
Trial: NCT06010472
Drug: anti-CD19 CAR NK cells (KN5501)
RxNorm normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive Fludarabine (25 mg/m2 per day) and Cyclophosphamide (300mg/m2 per day) on day -5, -4, and -3. Multiple doses of anti-CD19 CAR NK cells (KN5501) will infused in each group using the 3 + 3 dose-escalation strategy.
Trial: NCT06367205
Drug: Regular Fluid Therapy
RxNorm normalized name: amniotic fluid (bovine)
DrugBank: Human Amniotic Fluid (DB15871)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anesthesiologists will rely on their clinical expertise and intraoperative circulatory hemodynamic assessment to regulate fluid infusion rates and administer medications as necessary
Trial: NCT04857931
Drug: Colchicine
RxNorm normalized name: Colchicine
DrugBank: Colchicine (DB01394)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients meeting all inclusion criteria and no exclusion criteria will be randomly assigned to receive either colchicine (0.5mg once daily), colchicine (0.5mg twice daily) or matched placebo (1:1:1 allocation ratio), in addition to standard of care.
Trial: NCT05549401
Drug: CKD-348(4) F1
RxNorm normalized name: CKD-504
DrugBank: CKD-504 (DB18235)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QD, PQ
Trial: NCT05549401
Drug: CKD-348(4) F2
RxNorm normalized name: CKD-504
DrugBank: CKD-504 (DB18235)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QD, PQ
Trial: NCT06456138
Drug: Trametinib
RxNorm normalized name: Trametinib
DrugBank: Trametinib (DB08911)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Trametinib will be administrated orally every day.
Trial: NCT05900284
Drug: Metformin low dose
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: If randomized to the 500 mg. Metformin arm, a tablet will be administered orally to the study participant twice a day for the initial five days starting on the date of study enrollment. Clinical research coordinators will collect blood and urine samples from study participants in both treatment arms. The blood will be collected at Baseline, Day 1 thru 7, and at hospital discharge or Day 30, whichever occurs first. On Day 2 and Day 5, the blood will be collected at hour-based intervals of 0.5h, 1h, 2h, 4h, 8h, 12h for a pharmacokinetic profile and delivered to the University of Pittsburgh Medical Center Clinical Laboratory for analysis. The remaining blood collection tubes will be delivered to the Clinical Research Biospecimen Core laboratory to be processed, separated into microtubes, and stored at -80°. Urine samples will be collected at Baseline, Day 1, 3, and 5. The urine will be processed, separated into microtubes, and frozen at -80°.
Trial: NCT06456138
Drug: Anlotinib
RxNorm normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anlotinib will be administrated orally from day 1 to day 14 per 21-day cycle.
Trial: NCT06456138
Drug: Tislelizumab
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tislelizumab will be administered at full dose (200mg, Q3W) on the patient who received the efficacy evaluation of stable disease (SD) or partial response (PR) or complete response (CR) after 2 cycles' treatment of trametinib plus anlotinib.
Trial: NCT05900284
Drug: Metformin high dose
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: If randomized to the 1000 mg. Metformin arm, a tablet will be administered orally to the study participant twice a day for the initial five days starting on the date of study enrollment. Clinical research coordinators will collect blood and urine samples from study participants in both treatment arms. The blood will be collected at Baseline, Day 1 thru 7, and at hospital discharge or Day 30, whichever occurs first. On Day 2 and Day 5, the blood will be collected at hour-based intervals of 0.5h, 1h, 2h, 4h, 8h, 12h for a pharmacokinetic profile and delivered to the University of Pittsburgh Medical Center Clinical Laboratory for analysis. The remaining blood collection tubes will be delivered to the Clinical Research Biospecimen Core laboratory to be processed, separated into microtubes, and stored at -80°. Urine samples will be collected at Baseline, Day 1, 3, and 5. The urine will be processed, separated into microtubes, and frozen at -80°.
Trial: NCT06506838
Drug: Anlotinib
RxNorm normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For patients with the soft tissue sarcoma, the standard doxorubicin monotherapy regimen involves administering 37.5 mg/m² intravenously on days 1-2 of every 3 week . The treatment includes 3 cycles of neoadjuvant chemotherapy before surgery and 3 cycles of adjuvant chemotherapy after surgery, totaling 6 cycles. Anlotinib is administered at 12mg/d QD，day1\~14, 21d/cycle. Neoadjuvant radiotherapy is conducted before surgery, starting after the second chemotherapy cycle, using stereotactic body radiation therapy (SBRT) with a dose of 4\*10 Gy. Radical resection surgery is performed after the third chemotherapy cycle.
Trial: NCT06579066
Drug: Activated Charcoal
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will administer (activated charcoal) Charclone® 1000MG Tablet three times daily orally along with the standard care of therapy for duration of 4 weeks.
Trial: NCT05586815
Drug: Colistin
RxNorm normalized name: Colistin
DrugBank: Colistin (DB00803)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 150 mg every 8 hours intravenously for at least 7 and up to a maximum of 28 days
Trial: NCT04040660
Drug: NexoBrid
RxNorm normalized name: Nexobrid
DrugBank: Stem bromelain (DB12249)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NexoBrid is presented as lyophilized powder and gel vehicle for preparation of a gel for cutaneous use. The API is a concentrate of proteolytic enzymes enriched in Bromelain extracted from the stem of Ananas comosus (pineapple plant)
Trial: NCT05802628
Drug: Cetylpyridinium Chloride Buccal Tablets
RxNorm normalized name: Cetylpyridinium Chloride
DrugBank: Cetylpyridinium (DB11073)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects administrated single dose of Cetylpyridinium Chloride Buccal Tablet
Trial: NCT05968001
Drug: Obinutuzumab
RxNorm normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: obinutuzumab (G)-contained regimens, including GB, G-CHOP, and G-CVP.
Trial: NCT06357897
Drug: Local PEG4000
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PEG-Chula is developed from PEG 4000 used at King Chulalongkorn Memorial Hospital with added sweetener and flavours. Children will be given PEG-Chula at a dose of 0.5 - 1 g/kg/day.
Trial: NCT06357897
Drug: Commercial PEG4000
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: For commercial PEG, We use Forlax as the control group. Children will be given Forlax at a dose of 0.5 - 1 g/kg/day.
Trial: NCT05338099
Drug: EN001
RxNorm normalized name: ReN001
DrugBank: ReN001 (DB05236)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EN001 intravenously (IV) in the treatment of Duchenne Muscular Dystrophy (DMD) Dosage for each group is as follows.~Dose group A (Low dose): 5.0x10\^5 cells/kg
Trial: NCT05338099
Drug: EN001
RxNorm normalized name: ReN001
DrugBank: ReN001 (DB05236)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EN001 intravenously (IV) in the treatment of Duchenne Muscular Dystrophy (DMD) Dosage for each group is as follows.~Dose group B (High dose): 2.5x10\^6 cells/kg
Trial: NCT04542473
Drug: Ursodeoxycholic acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodiol C24H40O4 suspension
Trial: NCT06265545
Drug: Ivosidenib,Venetoclax,gilteritinib,Selinexor
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: if the target gene mutations are positive, enter arm1 or arm2. other conditions, enter the chemotherapy arms (Arm3-6)
Trial: NCT04983550
Drug: SG001
RxNorm normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant Anti-PD-1 Fully Human Monoclonal Antibody Injection, 240 mg q2w
Trial: NCT04983550
Drug: Doxorubicin hydrochloride liposome injection
RxNorm normalized name: doxorubicin hydrochloride liposome Injection
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin hydrochloride liposome injection 40mg/m \^2 q4w
Trial: NCT05098054
Drug: Soticlestat
RxNorm normalized name: Soticlestat
DrugBank: Soticlestat (DB16987)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soticlestat tablets.
Trial: NCT04570436
Drug: gabapentin 600 mg
RxNorm normalized name: gabapentin 600 MG
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: participants will receive an oral dose of gabapentin 600 mg
Trial: NCT04570436
Drug: gabapentin 1200 mg
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: participants will receive an oral dose of gabapentin 1200 mg
Trial: NCT04570436
Drug: gabapentin 1800 mg
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: participants will receive an oral dose of gabapentin 1800 mg
Trial: NCT04570436
Drug: diazepam 20 mg
RxNorm normalized name: diazePAM 20 mg rectal kit
DrugBank: Diazepam (DB00829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: participants will receive an oral dose of 20 mg dose of diazepam
Trial: NCT04920357
Drug: Vaccination
RxNorm normalized name: Multi-peptide vaccination
DrugBank: CoVac-1 (DB16429)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Persons that are vaccinated within the national and regional vaccine program are invited to participate in the follow-up study.
Trial: NCT05384626
Drug: NVL-655
RxNorm normalized name: NVL-655
DrugBank: NVL-655 (DB18682)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Tablet of NVL-655
Trial: NCT04079621
Drug: primaquine
RxNorm normalized name: Primaquine
DrugBank: Primaquine (DB01087)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Primaquine regimen over 7 days (0.5mg/kg/day for 7 days)
Trial: NCT06496048
Drug: Lurbinectedin
RxNorm normalized name: LURBINECTEDIN
DrugBank: Lurbinectedin (DB12674)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lurbinectedin 3.2 mg/m2 administered by infusion on Day 1 of each cycle (q3wk)
Trial: NCT06496048
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Irinotecan 75 mg/m² intravenously Days 1 \& 8 q3wk
Trial: NCT06496048
Drug: Lurbinectedin
RxNorm normalized name: LURBINECTEDIN
DrugBank: Lurbinectedin (DB12674)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lurbinectedin 2.0 mg/m2 administered by infusion on Day 1 of each cycle (q3wk)
Trial: NCT06496048
Drug: Topotecan
RxNorm normalized name: Topotecan
DrugBank: Topotecan (DB01030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topotecan 1.2 mg/m² intravenously Days 1-5 q3wk
Trial: NCT05431075
Drug: Amoxicillin
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Included in quadruple eradication medication.
Trial: NCT05431075
Drug: Bismuth Potassium Citrate
RxNorm normalized name: bismuth
DrugBank: Bismuth cation (DB14572)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Included in quadruple eradication medication.
Trial: NCT05431075
Drug: Colloidal Bismuth Pectin
RxNorm normalized name: bismuth / pectin
DrugBank: Pectin (DB11158)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Included in quadruple eradication medication.
Trial: NCT05431075
Drug: Esomeprazole 20mg
RxNorm normalized name: ESOMEPRAZOLE 20MG (BASE) CAP,EC
DrugBank: Esomeprazole (DB00736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Included in quadruple eradication medication.
Trial: NCT05536154
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Day 1\~Day 2: 75mg/m\^2
Trial: NCT05536154
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Day 1\~Day 2: 200mg/m\^2, q12h
Trial: NCT04672941
Drug: Tiotropium bromide plus Olodaterol
RxNorm normalized name: olodaterol / tiotropium
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium bromide plus Olodaterol
Trial: NCT05106179
Drug: Atenolol Pill
RxNorm normalized name: atenolol Pill
DrugBank: Atenolol (DB00335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atenolol is a second-generation hydrophilic β-1-selective adrenergic antagonist, which is primarily metabolised by the kidneys.
Trial: NCT05106179
Drug: Propranolol Pill
RxNorm normalized name: propranolol Pill
DrugBank: Propranolol (DB00571)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propranolol is highly lipophilic, nonselective β-blockers, which is primarily metabolised by the liver.
Trial: NCT05786716
Drug: Trastuzumab
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: An initial loading dose of 8 mg/kg body weight administered intravenously every 21 days followed thereafter by a maintenance dose of 6 mg/kg body weight.
Trial: NCT05786716
Drug: Pertuzumab
RxNorm normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: An initial loading dose of 14 mg/kg administered intravenously every 21 days followed thereafter by a maintenance dose of 7 mg/kg.
Trial: NCT05536349
Drug: Pirtobrutinib
RxNorm normalized name: Pirtobrutinib
DrugBank: Pirtobrutinib (DB17472)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given by PO